Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Med Virol
    May 2024
  1. LIU CH, Chang YP, Lee JY, Chen CY, et al
    Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
    J Med Virol. 2024;96:e29675.
    >> Share

    April 2024

  2. Retraction: "Small Interfering RNA Effectively Inhibits Protein Expression and Negative Strand RNA Synthesis From a Full-Length Hepatitis C Virus Clone".
    J Med Virol. 2024;96:e29574.
    >> Share

    March 2024
  3. CHEN X, Dong S, Shi Y, Wu Z, et al
    Biosensor-based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus.
    J Med Virol. 2024;96:e29481.
    >> Share

  4. MIUMA S, Miyaaki H, Ichikawa T, Matsuzaki T, et al
    Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.
    J Med Virol. 2024;96:e29432.
    >> Share

    February 2024
  5. CHEN B, Xu B, Cui HY, Ma ZH, et al
    Comparison of effectiveness and cost of different HCV testing strategies in high-risk populations in China.
    J Med Virol. 2024;96:e29433.
    >> Share

  6. LIU W, Li L, Yin M, Cao C, et al
    High-speed centrifugation rather than Lipoclear reagent can be used for removing the interference of lipemia on serological tests of infectious diseases: AIDS, hepatitis B, hepatitis C, and syphilis by chemiluminescent microparticle immunoassay.
    J Med Virol. 2024;96:e29385.
    >> Share

  7. LIU Y, Kim ES, Guo H
    Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures.
    J Med Virol. 2024;96:e29485.
    >> Share

    January 2024
  8. LI M, Wei Z, Su J, Wu X, et al
    Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.
    J Med Virol. 2024;96:e29405.
    >> Share

  9. ADHIKARI A, Abayasingam A, Brasher NA, Kim HN, et al
    Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes.
    J Med Virol. 2024;96:e29381.
    >> Share

    December 2023
  10. ABDEL-SAMIEE M, Youssef MI, Elghamry F, Bazeed M, et al
    A multicentric and nationwide predictive study role of T cell sub-population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients.
    J Med Virol. 2023;95:e29248.
    >> Share

  11. NGARI JW, Leumi S, Han L, Liu C, et al
    Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.
    J Med Virol. 2023;95:e29290.
    >> Share

    September 2023
  12. PENG X, Shi Y, Zhang B, Xu C, et al
    Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
    J Med Virol. 2023;95:e29084.
    >> Share

  13. LIU C, Guo M, Han L, Lu J, et al
    Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
    J Med Virol. 2023;95:e29103.
    >> Share

    August 2023
  14. ADACHI E, Saito M, Kikuchi T, Ikeuchi K, et al
    Incidence of sexually transmitted hepatitis C virus infection among men who have sex with men in Japan from 2009 to 2023.
    J Med Virol. 2023;95:e29039.
    >> Share

    July 2023
  15. LARA-AGUILAR V, Crespo-Bermejo C, Llamas-Adan M, Grande-Garcia S, et al
    HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
    J Med Virol. 2023;95:e28955.
    >> Share

  16. QU Y, Wang W, Xiao MZX, Zheng Y, et al
    The interplay between lipid droplets and virus infection.
    J Med Virol. 2023;95:e28967.
    >> Share

    March 2023
  17. WU B, Tobe RG, Yan M, Lin H, et al
    Trends of Global Burden Related to HBV and HCV from 1990 to 2019: An Age-Period-Cohort Analysis.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28663.
    >> Share

  18. PISATURO M, Alessio L, Starace M, Macera M, et al
    CHARACTERIZATION OF HEPATITIS VIRUS CO-INFECTIONS IN A COHORT OF IMMIGRANTS LIVING IN SOUTHERN ITALY.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
    >> Share

  19. FENG Z, Huang P, Zhang J, Xia X, et al
    KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
    >> Share

    February 2023
  20. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    >> Share

    January 2023
  21. MOHAMED AA, Esmail OE, Ibrahim AMA, Makled S, et al
    The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
    J Med Virol. 2023;95:e28343.
    >> Share

    November 2022
  22. ARANDHARA VL, Patrick McClure C, Tarr AW, Chappell S, et al
    SCAVENGER RECEPTOR CLASS B TYPE I GENETIC VARIANTS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC HEPATITIS C VIRUS INFECTION.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28331.
    >> Share

    September 2022
  23. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    >> Share

    August 2022
  24. PRICE AS, Nelson AK, Ghosh A, Kottilil S, et al
    A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28105.
    >> Share

    July 2022
  25. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    >> Share

    June 2022
  26. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    >> Share

    May 2022
  27. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    >> Share

  28. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    >> Share

  29. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    >> Share

    January 2022
  30. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    >> Share

    November 2021
  31. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    >> Share

    October 2021
  32. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    >> Share

    September 2021
  33. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    >> Share

  34. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    >> Share

    August 2021
  35. ZHOU R, Liu L, Wang Y
    Viral Proteins Recognized by Different TLRs.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27265.
    >> Share

    July 2021
  36. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    >> Share

    June 2021
  37. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    >> Share

  38. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    >> Share

    April 2021
  39. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    >> Share

    March 2021
  40. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    >> Share

  41. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    >> Share

    December 2020
  42. MIRANDA NTGP, de Souza RL, Monteiro JC, Costa IB, et al
    Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil.
    J Med Virol. 2020 Dec 25. doi: 10.1002/jmv.26759.
    >> Share

    November 2020
  43. CHUA JV, Ntem-Mensah A, Abutaleb A, Husson J, et al
    Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study.
    J Med Virol. 2020 Nov 5. doi: 10.1002/jmv.26652.
    >> Share

    December 2019
  44. KIM M, Kyung Lee Y, Park B, Jun Oh D, et al
    Hepatitis virus B and C infections are associated with an increased risk of non-Hodgkin lymphoma: A nested case-control study using a national sample cohort.
    J Med Virol. 2019 Dec 11. doi: 10.1002/jmv.25653.
    >> Share

    April 2019
  45. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016